$3.02
6.21%
Nasdaq, Apr 21, 07:46 pm CET
ISIN
US44934S2068
Symbol
ICAD

iCAD, Inc. Stock price

$3.22
+0.89 38.20% 1M
+1.27 65.13% 6M
+1.39 75.96% YTD
+1.66 106.41% 1Y
-0.07 2.13% 3Y
-5.74 64.06% 5Y
-6.25 66.00% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
+0.15 4.89%
ISIN
US44934S2068
Symbol
ICAD
Sector

Key metrics

Market capitalization $88.12m
Enterprise Value $71.27m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.63
P/S ratio (TTM) P/S ratio 4.49
P/B ratio (TTM) P/B ratio 2.96
Revenue growth (TTM) Revenue growth -4.15%
Revenue (TTM) Revenue $19.61m
EBIT (operating result TTM) EBIT $-6.27m
Free Cash Flow (TTM) Free Cash Flow $-4.11m
Cash position $17.21m
EPS (TTM) EPS $-0.21
P/E forward negative
P/S forward 4.47
EV/Sales forward 3.61
Short interest 1.00%
Show more

Is iCAD, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

iCAD, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a iCAD, Inc. forecast:

4x Hold
100%

Analyst Opinions

4 Analysts have issued a iCAD, Inc. forecast:

Hold
100%

Financial data from iCAD, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
20 20
4% 4%
100%
- Direct Costs 3.22 3.22
26% 26%
16%
16 16
2% 2%
84%
- Selling and Administrative Expenses 15 15
10% 10%
79%
- Research and Development Expense 6.61 6.61
11% 11%
34%
-5.65 -5.65
19% 19%
-29%
- Depreciation and Amortization 0.62 0.62
26% 26%
3%
EBIT (Operating Income) EBIT -6.27 -6.27
19% 19%
-32%
Net Profit -5.62 -5.62
1% 1%
-29%

In millions USD.

Don't miss a Thing! We will send you all news about iCAD, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

iCAD, Inc. Stock News

Neutral
Business Wire
4 days ago
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of iCAD, Inc. (NasdaqCM: ICAD) to RadNet, Inc. (NasdaqGM: RDNT). Under the terms of the proposed transaction, shareholders of iCAD will receive 0.0677 shares of RadNet for each share of iCAD that they own....
Neutral
Business Wire
6 days ago
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of iCAD, Inc. (NASDAQ: ICAD) to RadNet, Inc. for 0.0677 shares of RadNet common stock for each share of iCAD common stock is fair to iCAD shareholders. Halper Sadeh encourages iCAD shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zac...
Neutral
GlobeNewsWire
13 days ago
NASHUA, N.H., April 08, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today announced the appointment of Mark Koeniguer as Chief Commercial Officer (CCO), to lead the next phase of global growth for iCAD.
More iCAD, Inc. News

Company Profile

iCAD, Inc. is a medical technology company, which engages in the provision cancer detection and therapy solutions. It operates through the Cancer Detection and Cancer Therapy segments. The Cancer Detection segment include image analysis and workflow products. The Cancer Therapy segment consists radiation therapy products. The company was founded in 1984 and is headquartered in Nashua, NH.

Head office United States
CEO Dana Brown
Employees 66
Founded 1984
Website www.icadmed.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today